Alnylam Pharmace. buy Needham & Company LLC
Summary
This prediction is currently active. The price of Alnylam Pharmace. has decreased since the start of the prediction. Compared to the start price this results in a performance of -28.97%. This prediction currently runs until 12.09.24. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | 1.651% | 1.651% |
iShares Core DAX® | -0.552% | 3.405% |
iShares Nasdaq 100 | -1.415% | 4.613% |
iShares Nikkei 225® | -0.877% | -1.396% |
iShares S&P 500 | -0.415% | 3.338% |
Comments by Needham___Company_LL for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Needham___Company_LL for Alnylam Pharmace.
Alnylam Pharmace.
02.05.24
02.05.25
30.05.24
Alnylam Pharmace.
15.02.24
15.02.25
30.05.24
Alnylam Pharmace.
09.10.23
09.10.24
30.05.24
Alnylam Pharmace.
04.08.23
04.08.24
30.05.24